Literature DB >> 8735805

Signals elicited from human platelets by synthetic, triple helical, collagen-like peptides.

M Achison1, C Joel, P G Hargreaves, S O Sage, M J Barnes, R W Farndale.   

Abstract

Synthetic collagen-like peptides, of general structure [Gly-Pro-HyP]n, adopt the triple-helical structure which is essential for the platelet-reactivity of native collagens. These peptides are potent activators of platelets, stimulating platelet aggregation at much lower dose than collagen fibres, but, unlike collagen fibres, they are not recognised by the integrin alpha 2 beta 1. We have examined the ability of the synthetic peptides to activate the various signalling pathways which regulate human platelet function. The peptides are potent activators of Ca2+ mobilisation and of protein kinase C, and they stimulate tyrosine phosphorylation of some substrates preferentially. However, in contrast with native type I collagen fibres, they are unable to inhibit platelet adenylate cyclase. This suggests a mode of action for the synthetic peptides which substantially overlaps, but which is not entirely identical with, that of native collagen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735805     DOI: 10.1097/00001721-199603000-00009

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

1.  Monomeric (glycine-proline-hydroxyproline)10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI.

Authors:  J Asselin; C G Knight; R W Farndale; M J Barnes; S P Watson
Journal:  Biochem J       Date:  1999-04-15       Impact factor: 3.857

Review 2.  Synthesis and biological applications of collagen-model triple-helical peptides.

Authors:  Gregg B Fields
Journal:  Org Biomol Chem       Date:  2010-01-20       Impact factor: 3.876

3.  LAT is required for tyrosine phosphorylation of phospholipase cgamma2 and platelet activation by the collagen receptor GPVI.

Authors:  J M Pasquet; B Gross; L Quek; N Asazuma; W Zhang; C L Sommers; E Schweighoffer; V Tybulewicz; B Judd; J R Lee; G Koretzky; P E Love; L E Samelson; S P Watson
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.